Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease

Bartolome R. Celli, Nicholas Locantore, Julie Yates, Ruth Tal-Singer, Bruce E. Miller, Per Bakke, Peter Calverley, Harvey Coxson, Courtney Crim, Lisa D. Edwards, David A. Lomas, Annelyse Duvoix, William MacNee, Stephen Rennard, Edwin Silverman, Jørgen Vestbo, Emiel Wouters, Alvar Agustí

Research output: Contribution to journalArticle

241 Citations (Scopus)

Abstract

Rationale: Accurate prediction of mortality helps select patients for interventions aimed at improving outcome. Objectives: Because chronic obstructive pulmonary disease is characterized by low-grade systemic inflammation, we hypothesized that addition of inflammatory biomarkers to established predictive factors will improve accuracy. Methods: A total of 1,843 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study were followed for 3 years. Kaplan-Meier curves, log-rank analysis, and Cox proportional hazards analyses determined the predictive value for mortality of clinical variables, while C statistics assessed the added discriminative power offered by addition of biomarkers. Measurements and Main Results: At recruitment we measured anthropometrics, spirometry, 6-minute walk distance, dyspnea, BODE index, history of hospitalization, comorbidities, and computed tomography scan emphysema. White blood cell and neutrophil counts, serum or plasma levels of fibrinogen, chemokine ligand 18, surfactant protein D, C-reactive protein, Clara cell secretory protein-16, IL-6 and -8, and tumor necrosis factor-α were determined at recruitment and subsequent visits. A total of 168 of the 1,843 patients (9.1%) died. Non-survivors were older and hadmore severe airflow limitation, increased dyspnea, higher BODE score, more emphysema, and higher rates of comorbidities and history of hospitalizations. The best predictive model for mortality using clinical variables included age, BODE, and hospitalization history (C statistic of 0.686; P < 0.001). One single biomarker (IL-6) significantly improved the C statistic to 0.708, but this was further improved to 0.726 (P = 0.003) by the addition of all biomarkers. Conclusions: The addition of a panel of selected biomarkers improves the ability of established clinical variables to predict mortality in chronic obstructive pulmonary disease. Clinical trial registered with www.clinicaltrials.gov (NCT00292552).

Original languageEnglish (US)
Pages (from-to)1065-1072
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume185
Issue number10
DOIs
StatePublished - May 15 2012

Fingerprint

Chronic Obstructive Pulmonary Disease
Biomarkers
Mortality
Hospitalization
Emphysema
Dyspnea
Comorbidity
Interleukin-6
Uteroglobin
Dilatation and Curettage
Spirometry
Interleukin-8
Leukocyte Count
Chemokines
Surface-Active Agents
Fibrinogen
Proteins
Neutrophils
Tumor Necrosis Factor-alpha
History

Keywords

  • Biologic markers
  • Mortality
  • Prognosis
  • Pulmonary disease, chronic obstructive

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. / Celli, Bartolome R.; Locantore, Nicholas; Yates, Julie; Tal-Singer, Ruth; Miller, Bruce E.; Bakke, Per; Calverley, Peter; Coxson, Harvey; Crim, Courtney; Edwards, Lisa D.; Lomas, David A.; Duvoix, Annelyse; MacNee, William; Rennard, Stephen; Silverman, Edwin; Vestbo, Jørgen; Wouters, Emiel; Agustí, Alvar.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 185, No. 10, 15.05.2012, p. 1065-1072.

Research output: Contribution to journalArticle

Celli, BR, Locantore, N, Yates, J, Tal-Singer, R, Miller, BE, Bakke, P, Calverley, P, Coxson, H, Crim, C, Edwards, LD, Lomas, DA, Duvoix, A, MacNee, W, Rennard, S, Silverman, E, Vestbo, J, Wouters, E & Agustí, A 2012, 'Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 10, pp. 1065-1072. https://doi.org/10.1164/rccm.201110-1792OC
Celli, Bartolome R. ; Locantore, Nicholas ; Yates, Julie ; Tal-Singer, Ruth ; Miller, Bruce E. ; Bakke, Per ; Calverley, Peter ; Coxson, Harvey ; Crim, Courtney ; Edwards, Lisa D. ; Lomas, David A. ; Duvoix, Annelyse ; MacNee, William ; Rennard, Stephen ; Silverman, Edwin ; Vestbo, Jørgen ; Wouters, Emiel ; Agustí, Alvar. / Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. In: American Journal of Respiratory and Critical Care Medicine. 2012 ; Vol. 185, No. 10. pp. 1065-1072.
@article{b4a289464cf34c058ec43706393b41a6,
title = "Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease",
abstract = "Rationale: Accurate prediction of mortality helps select patients for interventions aimed at improving outcome. Objectives: Because chronic obstructive pulmonary disease is characterized by low-grade systemic inflammation, we hypothesized that addition of inflammatory biomarkers to established predictive factors will improve accuracy. Methods: A total of 1,843 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study were followed for 3 years. Kaplan-Meier curves, log-rank analysis, and Cox proportional hazards analyses determined the predictive value for mortality of clinical variables, while C statistics assessed the added discriminative power offered by addition of biomarkers. Measurements and Main Results: At recruitment we measured anthropometrics, spirometry, 6-minute walk distance, dyspnea, BODE index, history of hospitalization, comorbidities, and computed tomography scan emphysema. White blood cell and neutrophil counts, serum or plasma levels of fibrinogen, chemokine ligand 18, surfactant protein D, C-reactive protein, Clara cell secretory protein-16, IL-6 and -8, and tumor necrosis factor-α were determined at recruitment and subsequent visits. A total of 168 of the 1,843 patients (9.1{\%}) died. Non-survivors were older and hadmore severe airflow limitation, increased dyspnea, higher BODE score, more emphysema, and higher rates of comorbidities and history of hospitalizations. The best predictive model for mortality using clinical variables included age, BODE, and hospitalization history (C statistic of 0.686; P < 0.001). One single biomarker (IL-6) significantly improved the C statistic to 0.708, but this was further improved to 0.726 (P = 0.003) by the addition of all biomarkers. Conclusions: The addition of a panel of selected biomarkers improves the ability of established clinical variables to predict mortality in chronic obstructive pulmonary disease. Clinical trial registered with www.clinicaltrials.gov (NCT00292552).",
keywords = "Biologic markers, Mortality, Prognosis, Pulmonary disease, chronic obstructive",
author = "Celli, {Bartolome R.} and Nicholas Locantore and Julie Yates and Ruth Tal-Singer and Miller, {Bruce E.} and Per Bakke and Peter Calverley and Harvey Coxson and Courtney Crim and Edwards, {Lisa D.} and Lomas, {David A.} and Annelyse Duvoix and William MacNee and Stephen Rennard and Edwin Silverman and J{\o}rgen Vestbo and Emiel Wouters and Alvar Agust{\'i}",
year = "2012",
month = "5",
day = "15",
doi = "10.1164/rccm.201110-1792OC",
language = "English (US)",
volume = "185",
pages = "1065--1072",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "10",

}

TY - JOUR

T1 - Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease

AU - Celli, Bartolome R.

AU - Locantore, Nicholas

AU - Yates, Julie

AU - Tal-Singer, Ruth

AU - Miller, Bruce E.

AU - Bakke, Per

AU - Calverley, Peter

AU - Coxson, Harvey

AU - Crim, Courtney

AU - Edwards, Lisa D.

AU - Lomas, David A.

AU - Duvoix, Annelyse

AU - MacNee, William

AU - Rennard, Stephen

AU - Silverman, Edwin

AU - Vestbo, Jørgen

AU - Wouters, Emiel

AU - Agustí, Alvar

PY - 2012/5/15

Y1 - 2012/5/15

N2 - Rationale: Accurate prediction of mortality helps select patients for interventions aimed at improving outcome. Objectives: Because chronic obstructive pulmonary disease is characterized by low-grade systemic inflammation, we hypothesized that addition of inflammatory biomarkers to established predictive factors will improve accuracy. Methods: A total of 1,843 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study were followed for 3 years. Kaplan-Meier curves, log-rank analysis, and Cox proportional hazards analyses determined the predictive value for mortality of clinical variables, while C statistics assessed the added discriminative power offered by addition of biomarkers. Measurements and Main Results: At recruitment we measured anthropometrics, spirometry, 6-minute walk distance, dyspnea, BODE index, history of hospitalization, comorbidities, and computed tomography scan emphysema. White blood cell and neutrophil counts, serum or plasma levels of fibrinogen, chemokine ligand 18, surfactant protein D, C-reactive protein, Clara cell secretory protein-16, IL-6 and -8, and tumor necrosis factor-α were determined at recruitment and subsequent visits. A total of 168 of the 1,843 patients (9.1%) died. Non-survivors were older and hadmore severe airflow limitation, increased dyspnea, higher BODE score, more emphysema, and higher rates of comorbidities and history of hospitalizations. The best predictive model for mortality using clinical variables included age, BODE, and hospitalization history (C statistic of 0.686; P < 0.001). One single biomarker (IL-6) significantly improved the C statistic to 0.708, but this was further improved to 0.726 (P = 0.003) by the addition of all biomarkers. Conclusions: The addition of a panel of selected biomarkers improves the ability of established clinical variables to predict mortality in chronic obstructive pulmonary disease. Clinical trial registered with www.clinicaltrials.gov (NCT00292552).

AB - Rationale: Accurate prediction of mortality helps select patients for interventions aimed at improving outcome. Objectives: Because chronic obstructive pulmonary disease is characterized by low-grade systemic inflammation, we hypothesized that addition of inflammatory biomarkers to established predictive factors will improve accuracy. Methods: A total of 1,843 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study were followed for 3 years. Kaplan-Meier curves, log-rank analysis, and Cox proportional hazards analyses determined the predictive value for mortality of clinical variables, while C statistics assessed the added discriminative power offered by addition of biomarkers. Measurements and Main Results: At recruitment we measured anthropometrics, spirometry, 6-minute walk distance, dyspnea, BODE index, history of hospitalization, comorbidities, and computed tomography scan emphysema. White blood cell and neutrophil counts, serum or plasma levels of fibrinogen, chemokine ligand 18, surfactant protein D, C-reactive protein, Clara cell secretory protein-16, IL-6 and -8, and tumor necrosis factor-α were determined at recruitment and subsequent visits. A total of 168 of the 1,843 patients (9.1%) died. Non-survivors were older and hadmore severe airflow limitation, increased dyspnea, higher BODE score, more emphysema, and higher rates of comorbidities and history of hospitalizations. The best predictive model for mortality using clinical variables included age, BODE, and hospitalization history (C statistic of 0.686; P < 0.001). One single biomarker (IL-6) significantly improved the C statistic to 0.708, but this was further improved to 0.726 (P = 0.003) by the addition of all biomarkers. Conclusions: The addition of a panel of selected biomarkers improves the ability of established clinical variables to predict mortality in chronic obstructive pulmonary disease. Clinical trial registered with www.clinicaltrials.gov (NCT00292552).

KW - Biologic markers

KW - Mortality

KW - Prognosis

KW - Pulmonary disease, chronic obstructive

UR - http://www.scopus.com/inward/record.url?scp=84861410475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861410475&partnerID=8YFLogxK

U2 - 10.1164/rccm.201110-1792OC

DO - 10.1164/rccm.201110-1792OC

M3 - Article

C2 - 22427534

AN - SCOPUS:84861410475

VL - 185

SP - 1065

EP - 1072

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 10

ER -